Overview
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Recruiting
Trial end date:
2028-08-01
2028-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Criteria
Inclusion Criteria:- History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3
(Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment
regimens (Part 2)
- Measurable multiple myeloma (MM)
- Eastern Cooperative Oncology Group performance status of 0-1
Exclusion Criteria:
- Condition that confounds the ability to interpret data from the study
- Known active or history of central nervous system (CNS) involvement of MM
Note: Other protocol-defined inclusion/exclusion criteria apply